In the latest quarter, 5 analysts provided ratings for ResMed RMD, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

ResMed shares slumped and Eli Lilly shares gained after the FDA approved Eli Lilly's weight-loss treatment Zepbound for some patients with sleep apnea. Major U.S. indexes were mixed at midday ...

The news: Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts see a strong upside for stock prices of both companies. The ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Elon Musk has defended the H-1B visa scheme for immigrants. Elon Musk has given his not-so-polite verdict amid the ongoing online debate surrounding H-1B visa and immigration reform. In a fiery ...

Though McFly and Oasis also scored two Number 1s apiece – the former with All About You and I'll Be OK; the latter with Lyla and The Importance of Being Idle – they were all bested by the late ...

Album anniversaries make listeners feel their age, yet lift the same burden by returning them to the glorious music of their bygone days. In 2025, a number of albums will celebrate milestones.

Waves of intense cold will send temperatures plunging as much as 20F (11C) below normal across the central and eastern US this month, triggering ice storms that could down power lines and snarl ...

This guide discusses important themes and trends for the coming annual reporting season. It also includes a “housekeeping checklist” designed to assist you as you prepare your annual report ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...